ACT’s Chief Scientific Officer Robert Lanza, MD, Appointed Editor-in-Chief of BioResearch Open Access Journal  

  ACT’s Chief Scientific Officer Robert Lanza, MD, Appointed Editor-in-Chief
  of BioResearch Open Access Journal

Quality Peer-Reviewed Journal from Mary Ann Liebert Publishers Provides Forum
for Broad Spectrum of Scientific Topics Based on Innovative Open Access Model

Business Wire

MARLBOROUGH, Mass. -- February 11, 2013

Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC or the “Company”), a leader
in the regenerative medicine space, announced today that the Company’s chief
scientific officer, Robert Lanza, MD, has been appointed editor-in-chief of
the scientific journal BioResearch Open Access. The publication’s current
editor, Jane Taylor, Jane Taylor, PhD, MRC Centre for Regenerative Medicine,
University of Edinburgh, will continue in her role as Editor.

BioResearch Open Access, in its second year of publication, is a quality
peer-reviewed open access journal for the rapid-publication of a broad range
of scientific topics including but not limited to molecular and cellular
biology, tissue engineering and biomaterials, regenerative medicine, stem
cells, gene therapy, systems biology, genetics, biochemistry, virology,
microbiology, and neuroscience. The Journal welcomes basic science and
translational research in the form of original research articles,
comprehensive review articles, mini-reviews, rapid communications, brief
reports, technical reports, hypothesis articles, perspectives, and letters to
the editor. All articles in BioResearch Open Access are rapidly reviewed and
published online within 4 weeks of acceptance at www.liebertpub.com/biores.
Articles are fully open access and posted on the National Institutes of
Health’s (NIH) PubMedCentral. BioResearch Open Access is fully NIH-, HHMI-,
and Wellcome Trust-compliant.

"BioResearch Open Access is a fully-refereed multidisciplinary journal and
provides all the checks and balances that rigorous peer review ensures," said
Mary Ann Liebert, president of Mary Ann Liebert, Inc., publishers. "An
outstanding editorial team comprised of experienced journal editors guarantees
the integrity of the Journal, and we are very pleased to fortify it with the
appointment of Dr. Lanza."

According to the European Science Foundation’s Science Policy Briefing
(September 2012), “Open access publishing has the potential to revolutionise
the way in which biomedical scientists publish and access the latest results
in their field.”

Section editors of BioResearch Open Access include the following: James M.
Wilson, MD, PhD, University of Pennsylvania;  Antonios G. Mikos, PhD, Rice
University; Professor Sir Ian Wilmut, OBE FRS FRSE, University of Edinburgh; 
Peter C. Johnson, MD, Scintellix, LLC, Raleigh, NC; Aubrey D.N.J. de Grey,
PhD, SENS Foundation, Cambridge, UK;  Alan J. Russell, PhD, Carnegie Mellon
University; Thomas Hope, PhD, Northwestern University; Bruce A. Sullenger,
PhD, Duke University Medical Center; Graham C. Parker, PhD, Wayne State
University School of Medicine; Carol Shoshkes Reiss, PhD, New York
University;Stephen C. Ekker, PhD, Mayo Clinic, Rochester, MN; John B. West,
MD, PhD, University of California, San Diego; David L. Woodland, PhD, Chief
Scientific Officer, Keystone Symposia on Molecular and Cellular Biology; and
Eugene Kolker, PhD, Seattle Children's Hospital.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying cellular
technology in the field of regenerative medicine. For more information, visit
www.advancedcell.com.

About the Publisher of BioResearch Open Access

Mary Ann Liebert, Inc., is a privately held, fully integrated media company
known for establishing authoritative peer-reviewed journals in many promising
areas of science and biomedical research, including Tissue Engineering, Stem
Cells and Development, Human Gene Therapy and HGT Methods, and AIDS Research
and Human Retroviruses. Its biotechnology trade magazine, Genetic Engineering
& Biotechnology News (GEN), was the first in its field and is today the
industry’s most widely read publication worldwide. A complete list of the
firm’s 70 journals, books, and newsmagazines is available at
www.liebertpub.com.

Forward-Looking Statements

Statements in this news release regarding future financial and operating
results, future growth in research and development programs, potential
applications of our technology, opportunities for the company and any other
statements about the future expectations, beliefs, goals, plans, or prospects
expressed by management constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Any
statements that are not statements of historical fact (including statements
containing the words “will,” “believes,” “plans,” “anticipates,” “expects,”
“estimates,” and similar expressions) should also be considered to be
forward-looking statements. There are a number of important factors that could
cause actual results or events to differ materially from those indicated by
such forward-looking statements, including: limited operating history, need
for future capital, risks inherent in the development and commercialization of
potential products, protection of our intellectual property, and economic
conditions generally. Additional information on potential factors that could
affect our results and other risks and uncertainties are detailed from time to
time in the company’s periodic reports, including the report on Form 10-K for
the year ended December 31, 2011. Forward-looking statements are based on the
beliefs, opinions, and expectations of the company’s management at the time
they are made, and the company does not assume any obligation to update its
forward-looking statements if those beliefs, opinions, expectations, or other
circumstances should change. Forward-looking statements are based on the
beliefs, opinions, and expectations of the company’s management at the time
they are made, and the company does not assume any obligation to update its
forward-looking statements if those beliefs, opinions, expectations, or other
circumstances should change. There can be no assurance that the Company’s
clinical trials will be successful.

Contact:

Advanced Cell Technology, Inc.
Investors:
CEOcast, Inc.
James Young, 212-732-4300
or
Press:
ACT Corporate Communications
Bill Douglass, 646-450-3615
or
Russo Partners
Martina Schwarzkopf, Ph.D., 212-845-4292